UPDATE: BMO Capital Markets Raises PT on Isis Pharmaceuticals Following Development Head Meeting
April 19, 2013 at 11:00 AM EDT
In a report published Friday, BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on Isis Pharmaceuticals (NASDAQ: ISIS ), and raised the price target from $22.00 to $31.00. In the report, Birchenough noted, “The BMO Capital Markets US biotechnology team hosted a meeting this week with Isis Pharmaceuticals